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Summary. Gene therapy involves the use of specific 
genes to treat human diseases and is thus critically 
dependent on efficient gene delivery systems. Although 
a variety of systems for such gene delivery are under 
development, HSV has unique advantages in terms of its 
large genome size and for gene delivery in the nervous 
system because of its ability to enter a latent state in 
neuronal cells. Considerable progress has been made in 
the effective disablement of this virus whilst retaining its 
ability to deliver genes and in producing long term 
expression of the foreign gene. Although much remains 
to be achieved in the further disablement of the virus and 
its testing in rodent and primate models of human 
diseases, it is likely that these viruses may ultimately be 
of use in human gene therapy procedures particularly for 
otherwise intractable neurological diseases. 
Key words: Gene therapy, Herpes simplex virus, Virus 
vectors, Neurological diseases 
Introduction 
Gene Therapy is used to describe the delivery of a 
gene or genes to an individual suffering from a S ecific 
l! disease with the aim of achieving a therapeutic enefit 
(for an earlier review see Martin Duque et al., 1998). 
The most obvious exam les of this will be where an P individual is suffering rom the effects of a genetic 
disease caused by a mutation in a specific gene. In such 
cases, delivery of a functional copy of that gene could 
provide effective relief of the disease. As well as being 
applicable to such genetic diseases, the gene therapy 
approach is also applicable to situations other than those 
where the primary genetic defect is understood or which 
do not have a genetic component. Thus, for example, 
gene therap for cancer can involve the delivery of 
genes whic g stimulate an immune response to the 
tumour cells or which allow a non toxic pro-dru to be k converted to a toxic form by the cancer cell, t ereby 
killing the cell. Hence gene therapy can involve the 
delivery of genes which are of therapeutic benefit in the 
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disease regardless of whether the disease has a genetic 
component or whether such a genetic component is 
fully understood. 
This second type of gene therapy is particularly 
applicable in diseases of the nervous system where many 
of the complex diseases either do not have a simple 
genetic basis or that basis is not understood (for review 
see  Latchman, 1996). Thus, in neurodegenerative 
diseases such as motor neuron disease or Alzheimer's 
disease one could supply the gene encoding a 
neurotrophic factor which could promote survival of 
neurons that would otherwise die. Indeed, therapeutic 
benefit has been observed in an animal model of motor 
neuron disease when the genes encoding neurotrophin-3 
and ciliary neurotrophic factor were delivered with virus 
vectors (Haase et al., 1997). 
Similarly, it has been shown that the symptoms of 
Parkinson's disease can be relieved both in animal 
models and human individuals by the transplantation of 
foetal neurons, because such neurons provide a source of 
dopamine to replace the deficit of this substance caused 
by the loss of dopaminergic neurons during the course of 
the disease (Backlund et al., 1985). Hence, gene therapy 
for Parkinson's disease could be attempted by delivering 
the gene encoding tyrosine hydroxylase which is the rate 
limiting enzyme for dopamine production. Similarly, it 
would be possible to deliver the gene encoding glial 
derived neurotrophic (GDNF) factor since this factor has 
been shown to promote the survival of dopaminergic 
neurons and hence could be used to arrest the 
progressive loss of dopaminergic neurons which is 
characteristic of the disease (Opacka-Juffry et al., 1995; 
Lapchak, 1996; Lapchak et al., 1996). 
Methods of gene delivery 
These possibilities, have led numerous laboratories 
to attempt to develop means of effectively delivering 
genes in vivo. One means of doing this would be to 
transplant cells engineered to express the gene of 
interest.  Thus,  fetal neuronal transplants can be 
beneficial in neurological diseases (see above) but the 
material is  scarce and ethical difficulties arise. A 
possible solution would be to engineer non-neuronal 
dividing cel ls  such as  fibroblasts to produce the 






